Core Curriculum 2017 Flashcards Preview

Prostate cancer > Core Curriculum 2017 > Flashcards

Flashcards in Core Curriculum 2017 Deck (25)
Loading flashcards...
1
Q

What are the three metals used for brachytherapy?

A

Iodine-125, Palladium-103 and Iridium-192

2
Q

What are relative contraindications to radiation?

A

Prostate > 60 g, TURP, IPSS > 15

3
Q

What 3 trials show benefit of adjuvant radiation to prostate bed after radical prostatectomy?

A

EORTC 22911
ARO 9602
SWOG 8794

4
Q

What did SWOG 8794 show?

A

Adjuvant XRT improved OS compared to salvage. This was attributable to the number of patients with detectable PSA upon adjuvant treatment

5
Q

What did EORTC 22911 and ARO 9602 show?

A

improvement in bRFS but not OS or DMFS

6
Q

Which patients are likely to benefit from salvage XRT?

A
Gl < 7
pre-RT PSA < 2
neg SVI
(+) margins
PSA doubling time > 10 mo
7
Q

One in __ men will be diagnosed with prostate cancer during their lifetime.

A

7

8
Q

What percentage of men will die from prostate cancer?

A

2.8%

9
Q

What ages does AUA recommend offering CaP screening?

A

55-69

10
Q

What life expectancy should you stop offering screening?

A

10-15 year life expectancy

11
Q

The European Randomized Study of Screening for Prostate cancer reported what?

A

A statistically significant relative reduction of 21% in prostate cancer mortality at 11 years.

12
Q

What is very low risk prostate cancer per NCCN

A

PSA ≤ 10 ng/mL, Gleason score ≤ 6, clinical stage T1c, < 3 positive biopsy cores, ≤ 50% in each core, and PSA density < 0.15 ng/mL/g

13
Q

Per NCCN, define low risk prostate cancer

A

PSA < 10 ng/mL, Gleason score ≤ 6, and clinical stageT1-T2a

14
Q

Per NCCN, define intermediate risk prostate cancer

A

PSA 10 - 20, Gleason score ≤ 7, and clinical stage T2b-c

15
Q

Per NCCN, define high risk prostate cancer

A

PSA > 20, Gl 8-10, cT3a

16
Q

Per NCCN, define very high risk prostate cancer

A

cT3b - T4

17
Q

Define AUA low risk prostate cancer

A

PSA ≤ 10 ng/mL, Gleason score ≤ 6, clinical stage T1c or cT2a

18
Q

Define AUA intermediate risk prostate cancer

A

PSA > 10-20 ng/mL or Gleason score 7, or clinical stage T2b

19
Q

Define AUA high risk prostate cancer

A

PSA > 20 or Gleason score 8-10, or clinical stage ≥T2c

20
Q

What did the prostate cancer prevention trial show and in what patients?

A

in men with low risk of disease, PSA < 3, finasteride decreased overall relative risk of CaP by 25%

21
Q

What did the REDUCE trial show and on which patients?

A

men with PSA 2.5 to 10 & prior neg biopsy on dutasteride had a relative risk reduction of 25% and absolute risk reduction of 5% of prostate cancer

22
Q

Why did the FDA refuse to issue an indication for CaP chemoprevention with 5ARI?

A

risk of high grade cancer may be higher in those patients

23
Q

What did the SELECT trial show?

A

selenium and vitamin E made no difference in the rate of prostate cancer

24
Q

What did SPCG4 show? Scandinavian prostate cancer group study #4

A

improvement in overall and disease specific mortality in men undergoing radical prostatectomy

25
Q

PIVOT trial found what?

A

Radical prostatectomy did not improve OS or DSM but did reduce risk of mets with >= Gl 7